Dragonfly Receives FSA Approval

Calendar Icon Wednesday, 5th April 2022

Dragonfly Receives FSA Approval

Dragonfly Biosciences is pleased to advise that the entire range of Dragonfly CBD consumable products are now officially included on the UK Food Standards Agency (FSA) published list of compliant CBD products as of 31st March 2022. This is a major milestone in the Company’s journey, adding significant value and strengthening its leadership position in the CBD market.

The impact of this announcement is that Dragonfly CBD products are permitted to continue to be sold in the UK market with an opportunity to replace revenues from non-compliant brands and SKUs currently on shelf within our existing retail footprint and with new retailers who have been waiting for this announcement. This credential and approval not only support consumer confidence with safety standards, it also creates a reference for retail groups who operate under strict quality control protocols to establish and maintain trust with their customers.

 

Dragonfly has always operated within the framework of its own Code of Practice based on integrity, transparency and quality to earn the trust and loyalty of CBD consumers. Dragonfly’s early listing with national retailers in the UK such as Boots and subsequently with many retailers such as Tesco, Sainsbury’s, Amazon and eBay was approached with efficiency and success.

Since February 2022 when the Company advised the intention to defer its ASX listing, the Board and its advisers have been focused on establishing a revised valuation to take to market. The Company remains steadfastly committed to an ASX listing and to that point, will soon be in a position to announce some exciting developments for potential investors. Your opportunity to participate in the next phase of the Dragonfly story is coming soon. Stay tuned.